PARP1 and neoplasm: Clinical evaluation of the pharmacodynamic (PD) activity of PARP inhibitors has focused primarily on measuring inhibition of ex vivo enzymatic activity or PAR incorporation in tumor tissues and peripheral blood mononuclear cells (PBMCs).